Difference between revisions of "Afuresertib (GSK-2110183)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
| (11 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=642287 NCI Drug Dictionary]: An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. | |
| − | ==Preliminary | + | ==Preliminary data== |
===[[Multiple myeloma]]=== | ===[[Multiple myeloma]]=== | ||
| − | # Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. [ | + | # '''PKB112835:''' Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. [https://doi.org/10.1182/blood-2014-03-559963 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4229853/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25075128/ PubMed] [https://clinicaltrials.gov/study/NCT00881946 NCT00881946] |
| − | + | ==Also known as== | |
| − | [[Category: | + | *'''Code name:''' GSK-2110183 |
| + | |||
| + | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:AKT1 inhibitors]] | [[Category:AKT1 inhibitors]] | ||
| − | [[Category:Multiple myeloma medications]] | + | [[Category:Multiple myeloma medications (investigational)]] |
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 01:18, 6 July 2024
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis.
Preliminary data
Multiple myeloma
- PKB112835: Spencer A, Yoon SS, Harrison SJ, Morris SR, Smith DA, Brigandi RA, Gauvin J, Kumar R, Opalinska JB, Chen C. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. Epub 2014 Jul 29. link to original article link to PMC article PubMed NCT00881946
Also known as
- Code name: GSK-2110183